Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.52 |
| ▸ | TUBB | P07437 | 4/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884470 | 0.85 | KDM4E (0.58) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL20571055 | 0.85 | ALDH1A1 (0.50) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL3877334 | 0.84 | KDM4E (0.51) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL3023269 | 0.83 | KDM4E (0.50) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL24482983 | 0.82 | NR4A2 (0.54) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL6923911 | 0.82 | KDM4E (1.00) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL4877545 | 0.80 | KDM4E (0.67) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL34463677 | 0.78 | MEN1 (0.58) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL3879382 | 0.78 | MEN1 (0.58) | KDM4EHSD17B10MAPTALDH1A1GAA | |
| SCHEMBL5193898 | 0.78 | KDM4E (0.64) | KDM4EHSD17B10MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-7049445-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-05-23 | — | — | US | disclosed |
| US-6861444-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | GPR119, ADRB3, DBH | KDM4E 3207/4885HSD17B10 138/4885MAPT 4097/4885 |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | GPR119, GIPR, SLC5A2 | KDM4E 1397/4885HSD17B10 201/4885MAPT 4137/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | KDM4E 1070/4885HSD17B10 761/4885MAPT 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.